Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S.
Tsimafeyeu I, et al. Among authors: solomko e.
Eur J Cancer. 2016 Jul;61:20-8. doi: 10.1016/j.ejca.2016.03.068. Epub 2016 Apr 29.
Eur J Cancer. 2016.
PMID: 27136102